Pharmaceuticals Financial News

Subscribe to enjoy similar stories. Piramal Pharma Ltd has moved the Supreme Court against a Gujarat Pollution Control Board order directing the immediate closure of its Dahej manufacturing unit over alleged environmental violations. The company is also contesting a direction allowing the encashment of a ₹15 lakh bank guarantee.

Subscribe to enjoy similar stories. The White House on Thursday launched its drug-pricing website, dubbed TrumpRx, the culmination of efforts by the administration to bring down pharmaceutical costs for some consumers.

Subscribe to enjoy similar stories. New Delhi: India plans to impose anti-dumping duties on ethambutol hydrochloride—a critical input used in tuberculosis (TB) medicines—to curb cheap imports from China and Thailand, according to a government order reviewed by Mint.

Subscribe to enjoy similar stories. In a bid to stem the alarming opioid crisis, India's apex drug regulator plans an overhaul of the Drugs and Cosmetics Act to sharply raise punishments and fines that would deter illegal diversion of habit-forming pharmaceutical opioids, according to two government officials in the know and documents reviewed by Mint.

Subscribe to enjoy similar stories. best midcap stocks, nifty midcap 100, krbl share price, shakti pumps, undervalue stocks india, basmati rice exports, pharmaceutical manufacturing india, solar pump pm-kusum, india gate rice, midcap stock correction, nifty midcap performance, low pe stocks, stock market india, midcap investment ideas Mid cap stocks have faced significant selling pressure over the past few months. Over the past month alone, the Nifty Midcap 100 index has declined by 4.27%, from 60,816.10 to 58,256.

Subscribe to enjoy similar stories. India’s landmark free trade deal with the European Union, finalised on Tuesday, includes significant tariff cuts on exports of pharmaceutical products as well as optical, medical and surgical equipment from Europe to India. Tariffs on pharmaceutical exports from Europe to India will drop to zero from 11% for almost all products.

Subscribe to enjoy similar stories. Market corrections usually expose valuation excesses. Stocks that are priced for perfection tend to correct sharply as earnings visibility weakens and risk appetite declines.

Subscribe to enjoy similar stories. Mumbai: Tata Capital Healthcare Fund-backed Linux Laboratories, which is focused on central nervous system (CNS)-based domestic formulations, has appointed Avendus as an adviser to facilitate a capital raise, two people familiar with the matter said. The Chennai-based company aims to raise $50-70 million to fund its expansion plans through organic and inorganic growth, double down on its existing categories and widen its footprint beyond India, the people said on the condition of anonymity.

Subscribe to enjoy similar stories. India’s largest drugmaker Sun Pharma is reportedly bidding for American pharmaceutical company Organon in a deal that could potentially be worth $10 billion, which would make it the largest overseas acquisition by an Indian pharma company. The drugmaker has secured $10–14 billion in temporary ‘bridge loans’ to fund the move.

Subscribe to enjoy similar stories. Earlier this month Danish drugmaker Novo Nordisk launched its oral Wegovy weight-loss pill in the US, for "needle-averse patients". The starting dose is priced at $149 a month for patients paying in cash, compared to the injectable version's list price of more than $1,300.

Subscribe to enjoy similar stories. India’s ambitions to localize semiconductors and batteries hinge on an unglamorous but critical input: high-precision chemicals. As the country pushes to reduce dependence on imports across strategic supply chains, one mid-sized chemical company is quietly attempting something rare - leveraging its pharmaceutical chemistry roots to position itself at the intersection of both industries.

Subscribe to enjoy similar stories. Imagine Reinhold Messner reaching the summit of Everest only to look back at the trail of climbers behind him, and thinking: I’m going to go a little further. With that, he leaps off the top of the highest peak in the world into the vast, icy vacuum below.

Subscribe to enjoy similar stories. As India’s pharmaceutical sector kicks off its earnings season for the quarter ended December on Friday, analysts expect muted margins. A key reason for this is the loss of patent exclusivity for the blood cancer drug Revlimid in the US.

legal battles between domestic generic drug manufacturers and global innovators, reigniting the debate over striking a balance between innovation protection and broader drug accessibility.Looking ahead to another year of patent challenges, Mint examines who ultimately benefits from these challenges.New drugs or methods of making them are typically protected by patents under intellectual property (IP) rights. The patent grants the innovator exclusive rights to market the drug for a set period, typically 20 years.

Mint.The proposed change aims to build a comprehensive database of bulk drug traders, improve traceability of imported raw materials, over 70% of which come from China, and allow regulators to quickly identify and hold accountable specific dealers involved in the supply of substandard inputs in India’s $50-billion pharmaceutical market.The new mechanism would dismantle the umbrella approach in the current common licensing system for raw materials and finished medicines, give the Drugs Controller General of India (DCGI) a long-missing registry of nearly 1.2 million bulk drug traders, and significantly strengthen traceability and accountability in the country's pharmaceutical market.The government move comes in the backdrop of India’s reputation as the ‘Pharmacy of the World’ taking a hit due to deaths of children in Uzbekistan, Gambia, Cameroon and India linked to cough syrups manufactured by Indian firms.As per the officials, a draft notification is in the works for this separate licensing regime for active pharmaceutical ingredients (APIs), including bulk drugs and advanced intermediates, which were valued at approximately $3.5 billion in FY25.While the total value for India's total pharmaceutical-related imports—including finished products—for FY24 was approximately $8.2 billion, bulk drugs remain the dominant share of this inflow data from the Directorate General of Commercial Intelligence and Statistics and commerce ministry shows.India’s API market is projected to reach $38.13 billion by 2034, growing at a CAGR of 8.50% from 2025 to 2034, according to reports by research firms like Market Research Future.“The lack of transparency in the raw material supply chain was highlighted by recent reports of cough syrups

salary hikes.The changing balance of power is visible in attrition data. According to a Mercer study, voluntary attrition across India Inc stood at 13.1% in 2023 and fell to 11.7% in 2024.

The growing popularity of obesity drugs is expected to spur Indian pharma companies to sign licensing partnerships and distribution deals as they eye the lucrative segment. Indian companies started signing big-ticket deals with innovators for novel GLP-1s, as well as generic versions, last year.

Mint in an interview.From JSW Paints acquiring AkzoNobel to Torrent Group acquiring J.B. Chemicals & Pharmaceuticals to Bajaj Finance buying out Allianz, growth-hungry Indian business groups are now making substantive M&A moves, he said.“We have seen that capital from global investors is headed towards India, and domestic capital continues to flow unabated.

In a development that is alarming policy makers and public health experts, India's oral nicotine pouch manufacturers are seeking permission to sell products of 6mg strength that are 50% more potent than the current maximum, offering them as therapeutic medical products under the nicotine replacement therapy (NRT) regime, according to two officials and documents reviewed by Mint.With the government running awareness campaigns against tobacco use in the country, this has sparked concerns of nicotine initiation and long-term addiction.The latest development pertains to Vcherish Pvt. Ltd, Harsh Nutricare Pvt.

Dear reader, as 2025, a year of global tumult and volatility, rolls by, Mint's reporters and columnists look around the corner on what is coming in 2026—to help you know what to expect and prepare for it. Tell us what you think at [email protected]’s trade policy in 2025 unfolded against a challenging global backdrop of high US tariffs, geopolitical uncertainty and slowing global demand.

pharmaceutical sector, a major global supplier of generic medicines.The revised Schedule M GMP had been earlier extended from the previous 1 January 2025 cutoff. The proposed extension for MSMEs, which have revenue of ₹250 crore or less, comes in the backdrop of less than a third of them submitting their upgrade plans, with the remaining units risking immediate closure and penalties.There are a total of 10,500 drug manufacturing units in India, of which 8,500 fall under the MSME category.